Enlivex Therapeutics (NASDAQ:ENLV) Lowered to “Strong Sell” Rating by Wall Street Zen

Wall Street Zen cut shares of Enlivex Therapeutics (NASDAQ:ENLV) to a strong sell rating in a report issued on Saturday morning.

Other equities analysts also recently issued research reports about the company. HC Wainwright reissued a “buy” rating and set a $7.00 price target on shares of Enlivex Therapeutics in a research report on Tuesday, September 2nd. D Boral Capital downgraded Enlivex Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, November 24th. D. Boral Capital reiterated a “hold” rating on shares of Enlivex Therapeutics in a report on Monday, November 24th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Enlivex Therapeutics in a research report on Monday, December 22nd. One research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Enlivex Therapeutics presently has an average rating of “Hold” and a consensus price target of $10.00.

Enlivex Therapeutics Stock Down 3.3%

ENLV opened at $0.75 on Friday. The firm has a 50 day moving average price of $0.98 and a 200-day moving average price of $1.10. Enlivex Therapeutics has a twelve month low of $0.73 and a twelve month high of $2.10. The stock has a market capitalization of $18.16 million, a price-to-earnings ratio of -1.36 and a beta of 1.49.

Enlivex Therapeutics (NASDAQ:ENLV) last announced its quarterly earnings results on Friday, November 14th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.03. As a group, analysts expect that Enlivex Therapeutics will post -0.7 earnings per share for the current year.

Institutional Trading of Enlivex Therapeutics

Several hedge funds have recently modified their holdings of the company. Citizens Financial Group Inc. RI bought a new stake in shares of Enlivex Therapeutics in the 3rd quarter valued at about $241,000. Jane Street Group LLC lifted its position in Enlivex Therapeutics by 527.4% during the first quarter. Jane Street Group LLC now owns 80,759 shares of the company’s stock valued at $78,000 after acquiring an additional 67,886 shares during the last quarter. Finally, Susquehanna International Group LLP acquired a new stake in Enlivex Therapeutics in the third quarter valued at approximately $57,000. 1.02% of the stock is owned by hedge funds and other institutional investors.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics is a clinical-stage biopharmaceutical company headquartered in Ness Ziona, Israel, that focuses on developing innovative immunotherapies for life-threatening inflammatory conditions. Founded in 2015, the company trades on the NASDAQ under the symbol ENLV and leverages a proprietary cell-based platform to restore immune balance in critical care settings.

The company’s lead product candidate, Allocetra, comprises reprogrammed apoptotic cell therapy designed to recalibrate the innate immune system.